Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Provided By GlobeNewswire
Last update: Jan 6, 2025
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025
Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones
Read more at globenewswire.comFORTRESS BIOTECH INC - FBIO 9 3/8 PERP
NASDAQ:FBIOP (12/12/2025, 8:00:01 PM)
7.7079
+0.01 (+0.1%)
2.93
-0.01 (-0.34%)
Find more stocks in the Stock Screener
